Advaxis and Vibalogics to Co-Develop Stable Storage Formulation for Live Vaccines
Marketing Potential Across Global Biologics Industry
NORTH BRUNSWICK, N.J.-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis.
Most live vaccines are stored via freeze drying called lyophilization. This drying method may not be suitable for all products, as it frequently kills most of the microorganism; depending upon the organism type and related recovery and stability issues. Based on Vibalogics' drying experience, a new method has been found that allows for a room temperature, storage-stable form of Advaxis' live Listeria vaccines with a very high recovery.
"This process, which we are currently developing for our Listeria immunotherapeutics, shows promise in its use with other living micro-organisms," commented Advaxis Chairman/CEO Thomas A. Moore. "Although it is intended for use with Listeria, other companies and academic institutions that use living microorganisms (e.g., Salmonella, E. coli) may benefit from this process. This initiative does not require significant development funds from Advaxis, vastly increases the commercial properties of our products, and can increase our short- and long-term shareholder value."
About Vibalogics, GmbH
Vibalogics is a partner for companies committed to developing therapeutic and prophylactic vaccines and biologics. The company is a single site for GMP-compliant manufacturing, formulating, filling and lyophilization of drugs based on recombinant or wild-type viruses and bacteria. The drugs are predominantly used for vaccinations, treatment of life-threatening diseases, virotherapy or gene therapy.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research - UK. Advaxis' technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board.
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc.
Released August 11, 2010